542a href=mailto:lpokras@lavidgecomlpokras@lavidgecom/a Milwaukee Bucks 542a href=mailto:lpokras@lavidge

542,, clarifies milwalkee bucks both of andrew bogut uncovers The Lavidge Company, +1-480-998-2600, for i/oData Centers; or Sarah Slade of i/o Data Centers, 1-866-282-5451,. BURLINGTON, Mass., Jan Bucks . 8 /PRNewswire-FirstCall/ -- Palomar MedicalTechnologies, Inc. (Nasdaq: PMTI), a leading researcher and developer oflight-based systems for cosmetic treatments, today announced the terminationof its international distribution agreement with the Swedish company Q-MED AB(OMX Nordic Exchange, Stockholm Mid Cap:QMED), a leading biotech/medicaldevice company based in Uppsala, Sweden.The international distributionagreement was originally entered into in January 2008 with the intention thatQ-MED would eventually be responsible for the marketing, advertising,promotion, sale and distribution of Palomar's professional products foraesthetic treatments outside North America.Due to the downturn in the world-wide economic environment, Q-MED's effortsare being concentrated on their own product line of dermal fillers.BothPalomar and Q-MED agreed that Palomar will be better served by separatelycontinuing to expand its existing distribution channel Joseph P. Caruso, Palomar Chief Executive Officer said, "Although we arechoosing to end our distribution agreement, this was a good learningexperience and we have forged a positive relationship with Q-MED that may bebeneficial in the future.We believe that during these challenging economictimes we will be better positioned with full control of our internationaldistribution.We have signed up many new distributors over the past twelvemonths and continue to work closely with all of our distributors to helpmaximize their sales efforts.Territories outside North America shouldcontinue to provide growth opportunities for us as we expand our efforts."Bengt Agerup, Q-MED Chief Executive Officer said, "By working closely withPalomar we have learned more about Palomar's top-end technological platformsand products. Considering the present challenging market conditions, Q-Med isfocusing on its leading dermal filler product line, Restylane(R) as well as onthe on-going launch of Macrolane(TM), the first injectable body contouringproduct line, and the Restylane Vital(TM) product line for skin rejuvenation.Hopefully we will be able to utilize our relationship and the knowledge wehave built in the future. "About Palomar Medical Technologies, Inc.: Palomar is a leading researcher anddeveloper of light-based systems for cosmetic treatments.

Palomar pioneeredthe optical hair removal field, when, in 1997, it introduced the firsthigh-powered laser hair removal system bucks milwaukee schedule . Since then, many of the major advancesin light-based hair removal have been based on Palomar technology bio bucks Milwaukee Bucks . In December2006, Palomar became the first company to receive a 510(k) over-the-counter(OTC) clearance from the United States Food and Drug Administration (FDA) fora new, patented, home use, light-based hair removal device bogut bucks . OTC clearanceallows the product to be marketed and sold directly to consumers without aprescription bradley center . There are now millions of light-based cosmetic proceduresperformed around the world every year in physician offices, clinics, spas andsalons.Palomar is testing many new and exciting applications to furtheradvance the hair removal market and other cosmetic applications. Palomar isfocused on developing proprietary light-based technology for introduction tothe mass markets nba.com - bucks . Palomar has granted The Procter & Gamble Company anon-exclusive License Agreement to certain patents, technology and FDAdocuments related to the home-use, light-based hair removal field for women bucks.com .In addition, Palomar has an exclusive development and license agreement withJohnson & Johnson Consumer Companies to develop and potentially commercializehome-use, light-based devices for reducing or reshaping body fat includingcellulite, reducing the appearance of skin aging, and reducing or preventingacne.For more information on Palomar and its products, visit Palomar's website at

To continue receiving the most up-to-date informationand latest news on Palomar as it happens, sign up to receive automatic e-mailalerts by going to the Investor Relations section of the website.About Q-MED AB: Q-MED AB is a rapidly growing and profitablebiotechnology/medical device company milwaukee bucks cheerleading competition . The company develops, manufactures,markets, and sells primarily medical implants bradley center bucks . The majority of the productsare based on the company's patented technology, NASHA(TM), for the productionof stabilized non-animal hyaluronic acid bradley center wi . The product portfolio todaycontains: Restylane(R) for filling lines and folds, contouring and creatingvolume in the face, Macrolane(TM) for body contouring, Durolane(TM) for thetreatment of osteoarthritis of the hip and knee joints, Deflux(TM) for thetreatment of vesicoureteral reflux, VUR, (a malformation of the urinarybladder) in children, Zuidex(TM) for the treatment of stress urinaryincontinence in women, and Solesta(TM) for the treatment of fecalincontinence bucks . Sales are made through the company's own subsidiaries ordistributors in over 70 countries. QMED today has just over 700 coworkers,with close to 500 at the company's head office and production facility inUppsala, Sweden. Q-MED AB is listed in the Mid Cap segment of the OMX NordicExchange in Stockholm.For more information on Q-MED and its products, visit Q-MED's website at

To continue receiving the most up-to-date information andlatest news on Q-MED as it happens, sign up to receive automatic e-mail alertsby going to the Investor Relations section of the website.This press release contains forward-looking statements within the meaning ofthe U.S milwaukee bucks payroll . Private Securities Litigation Reform Act of 1995.Forward-lookingstatements are based on the Company's current expectations, plans, intentions,beliefs or predictions bucks basketball . These forward-looking statements are neither promisesnor guarantees, but involve risk and uncertainties that may individually ormutually impact the matters herein, and cause actual results, events andperformance to differ materially from such forward-looking statements bucks blog Milwaukee Bucks tickets - nba . Theserisk factors include, but are not limited to, results of future operations,technological difficulties in developing or introducing new products, theresults of future research, lack of product demand and market acceptance forcurrent and future products, the effect of economic conditions, challenges inmanaging joint ventures and research with third parties and governmentcontracts, the impact of competitive products and pricing, governmentalregulations with respect to medical devices, including whether FDA clearancewill be obtained for future products and additional applications, the resultsof litigation, including patent infringement lawsuits, difficulties incollecting royalties, potential infringement of third-party intellectualproperty rights, factors affecting the Company's future income and resultingability to utilize its NOLs, and/or other factors, which are detailed fromtime to time in the Company's SEC reports, including the report on Form 10-Kfor the year ended December 31, 2007 and the Company's quarterly reports onForm 10-Q bucks forum . Readers are cautioned not to place undue reliance on theseforward-looking statements, which speak only as of the date hereof. TheCompany undertakes no obligation to release publicly the result of anyrevisions to these forward-looking statements that may be made to reflectevents or circumstances after the date hereof or to reflect the occurrence ofunanticipated events.Contacts:Kayla CastleInvestor Relations ManagerPalomar Medical Technologies, Q-MED AB Publ.Bengt Agerup, Chief Executive OfficerTel: +46 (0)70 974 9025Anders Blom, Sr.

Director Corporate Development & StrategyTel: +46 (0)70 974 9060SOURCEPalomar Medical Technologies, Inc.Kayla Castle, Investor Relations Manager of Palomar Medical Technologies,Inc Milwaukee Bucks tickets ., +1-781-993-2411, , or Bengt Agerup, Chief ExecutiveOfficer, +46 (0)70 974 9025, or Anders Blom, Sr . Director CorporateDevelopment & Strategy, +46 (0)70 974 9060, both ofQ-MED AB Publ. bucks game . Everyone has that friend Milwaukee Bucks - wikipedia .You know the type Deep down, he?s a good guy, really bucks history . But he?s never been able to hold a long-term relationship.Time after time, girl after girl, he gets the same result?a failed relationship . Even when things start out magically, they never end well.And every time this happens, he blames the girl It was her fault it didn?t work out She was the one who didn?t make the necessary changes Bucks tickets .

"I am hoping it is like riding a bike and that the players who have played in big football games will remember how to play," said coach Holtz.  "I worry most about our skill positions. We haven't played in a complete game, and sometimes the mind is willing but the body isn't. But whatever happens, I have told the players to have fun and to represent themselves and the University of Notre Dame with pride."Ron Israel, of The Legends team warned his teammates of Japan wide receiver Noriaki Kinoshita: “He’s fast and he’ll get by you if you can’t jam him at the line of scrimmage,“ said Israel.Israel knows about Kinoshita by way of playing alongside him, as they both played for the Amsterdam Admirals of the NFL Europe in 2005 Bucks tickets - nba . On Tuesday, Kaiser Aluminum, which itself emerged from fouryears of Chapter 11 bankruptcy protection in 2006, posted aquarterly loss, which it attributed largely to decliningproduction and one-time charges. On most franchises, Blanton would be considered the best ever Unfortunately for him, he followed Hall of Famer Paul Brown. All clear now for the next round.9:54PM: Pujols goes Happy Gilmore-esque with the pre-leg-kick during the swing. Execution is Morrow's downfall, and repetitions would hopefully do wonders.As for Joba Chamberlain, he should go to the bullpen Phil Hughes can take his spot in the rotation.